TP53 and Patent ductus arteriosus: Furthermore, SLC45A4 acted as an essential glucose transporter, and its knockdown induced autophagy in the TP53 mutant PDA cells; thus, it may serve as a novel marker and potential therapeutic target for TP53 mutant PDA.